

![]() |
Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al |
|
Authors | ||
Published in | Arthritis and rheumatism. 2008, vol. 58, no. 2, p. 635-6 | |
Keywords | Anti-Inflammatory Agents, Non-Steroidal/therapeutic use — Antibodies, Antiphospholipid/blood — Antiphospholipid Syndrome/drug therapy/epidemiology/immunology — Aspirin/therapeutic use — Humans — Risk Factors — Thrombosis/epidemiology/immunology/prevention & control | |
Identifiers | DOI: 10.1002/art.23160 PMID: 18240250 | |
Note | With author reply (p. 636) - Comment on: Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007 Jul;56(7):2382-91. | |
Full text | ||
Structures | ||
Research groups | Geneva Platelet Group (13) La maladie thromboembolique veineuse (808) | |
Citation (ISO format) | WAHL, Denis, LECOMPTE, Thomas Pierre, BOUNAMEAUX, Henri. Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al. In: Arthritis and rheumatism, 2008, vol. 58, n° 2, p. 635-6. doi: 10.1002/art.23160 https://archive-ouverte.unige.ch/unige:1837 |